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Purpose/Objective: To evaluate the prognostic significance of 
quantitative advanced imaging features derived from diagnostic CT 
images in HNSCC patients.We hypothesized that non-invasive imaging 
features of the tumor such as heterogeneity and shape extracted from 
already available CT images are prognostic for survival. 
Materials and Methods: Retrospective analysis of 150 patients with 
SCC of the head and neck (49 larynx and 101 oropharynx tumors) 
treated with radiotherapy alone or chemo-radiation with curative 
intent. All patients underwent a CT scan for treatment planning. The 
primary tumor was delineated by an experienced radiation oncologist 
on CT images. A set of 80 imaging features were automatically 
extracted from the tumor region on the CT scan, including 15 first 
order statistics, 33 textural features derived from gray level co-
occurrence and rung-length matrices, 24 textural wavelet features 
and 7 tumor shape metrics (Fig 1). For comparisons of CT features the 
Mann-Whitney U test was used to determine differences on overall 
survival. For TNM the Chi-square test was used. The Relieff algorithm 
was used to rank the CT features according to their importance 
attributes. Univariate and multivariate Cox proportional hazards 
models were used to compare the risk of death among patients. The 
performance of the model was evaluated with a 5-fold cross validated 
c-index.  
 
 Figure 1. Patients underwent a CT scan for treatment planning. The 
primary tumor was delineated by a radiation oncologist on the CT 
scan. The extracted CT features were evaluated for their association 
with overall survival.  
Results: The median survival was 64 months (95% CI, 58-71 months) 
and the median follow up was 35 months(range: 0.7-94), with a death 
event rate of 34 %. The results of the univariate analysis are shown in 
Table 1 for the top ranked features and for examples of features that 
were not significant. 39 CT features had significant differences among 
the overall survival groups. The combination of the top four 
parameters in the univariate analysis in a multivariate model rendered 
c-index of 0.77(CI, 0.69 – 0.83). This c-index was better than the 
observed for TNM. 
 
 
Conclusions: This preliminary analysis shows that advanced textural 
and shape features are prognostic for survival in HNSCC patients. The 
multivariate model based on CT features and even individual CT 
features had a better discriminatory power than TNM for survival. 
Further analysis involves the association of CT features with loco-
regional tumor control and a sub-analysis per tumor anatomical 
location. External validation of these results will follow.  
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Purpose/Objective: Treatment of head and neck squamous cell 
carcinomas (HNSCC) with radiotherapy and the epidermal growth 
factor (EGFR) inhibitor cetuximab has shown promising results, but is 
only effective in a fraction of HNSCC patients. Patient selection is 
based on EGFR expression as determined immunohistochemically, but 
this does not correlate with treatment response. The aim of this study 
was to develop and characterize the 111In-cetuximab-F(ab’)2 tracer for 
imaging EGFR expression and to determine if tracer uptake correlates 
with response to EGFR-inhibitor treatment in HNSCC xenografts. 
Materials and Methods: The optimal protein dose and imaging time-
point was determined in athymic mice with s.c. FaDu xenografts. 
Subsequently, mice with HNSCC xenografts SCCNij202, 167, 185 and 
153 were imaged with 111In-cetuximab-F(ab’)2. 
Results: The highest uptake of 111In-cetuximab-F(ab’)2 in FaDu tuors 
was obtained at doses of 5 µg/mouse (13.50 ± 5.17 %ID/g). Due to the 
rapid blood clearance, tumor-to-blood ratios were high for 111In-
cetuximab-F(ab’)2 (31.4 ± 3.8 at 24 h p.i.). MicroSPECT images showed 
preferential uptake in HNSCC xenografts; 3.1 ± 0.2 (SCCNij202), 2.8 ± 
0.4 (SCCNij153), 2.0 ± 0.8 (SCCNij185), 2.0 ± 0.4 (SCCNij167) %ID/g. 
Overall tumor uptake of 111In-cetuximab-F(ab’)2 correlated well with 
immuno-histochemical EGFR fractions (r=0.61, p<0.01). Growth delay 
experiments showed that SCCNij202 responded to cetuximab 
treatment whereas SCCNij167, SCCNij185 and SCCNij153 were non-
responders. 
Conclusions: 111In-cetuximab-F(ab’)2 showed a clear heterogeneous 
distribution throughout the tumor. Tumor uptake correlated with 
treatment response in three out of four HNSCC xenografts.  
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Purpose/Objective: Among head and neck cancer survivors many 
experience diminished quality of life owing to side effects following 
treatment; one of the predominant side effects is dysphagia, 
regardless of the treatment modality involved. The aim of this study 
was to investigate frequency, intensity and dose-volume 
characteristics for late dysphagia in head and neck cancer patients 
treated with curative IMRT.  
Table 1. Univariate analysis of CT imaging features and for their
association with survival 
 5 year survival 
= Yes  
(n = 99) 
5 year survival 
= No  
(n = 51) 
p C-
index 
Wavelet_Texture_1 3.0306 ±1.2007 5.4806 ± 7.6906 0.000 0.78 
Shape_3 56.22 ± 104.45 105.44 ± 78.48 0.000 0.77 
Volume 28.27 ± 104.01 55.87 ± 64.63 0.000 0.76 
Shape_5 0.65 ± 0.69 1.15 ± 0.72 0.000 0.76 
Shape_4 4.54 ±2.67 2.71 ± 1.03 0.000 0.74 
TNM 
1 
2 
3 
4 
33 
25 
13 
28 
8 
9 
12 
22 
0.028 0.66 
Texture_1st_6 1054.41 ± 26.80 1064.79 ± 22.53 0.131 0.58 
Texture_1st_4 1068.22 ± 17.13 1070.21 ± 14.19 0.982 0.44 
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Materials and Methods: Candidates for the study were recurrence-
free patients treated with primary radiotherapy (IMRT) for oral, 
pharyngeal and laryngeal cancer from 2006 to 2011 and attending 
follow-up between January1st and May 7th 2012. A total of 65 patients 
(44%) accepted the invitation to participate in a follow-up study 
including Modified Barium Swallow (MBS), EORTC QLQ C30 and H&N35, 
mouth opening, Charlsons co-morbidity index and smoking status. 
Data on patient, tumor and treatment characteristics were obtained 
from the DAHANCA database: Larynx 37%, pharynx 52%, oral cavity 
11%; median age 63 years, 85% men, 57% stage IV disease; weekly 
cisplatin 41%, Zalutumumab 16%. DVHs of the following OARs were 
analyzed: pharyngeal constrictor muscles (sup, mid. and inf. PCM), 
cricopharyngeal muscle, esophagus inlet muscle (EIM), cervical 
esophagus (CE), base of tongue, glottic and supraglottic larynx. Data 
were analyzed with dichotomized endpoints and logistic regression 
models. 
Results: Median follow-up after treatment was 3.3 years (range 1.0 - 
5.3).There was no significant difference between participants and 
non-participants regarding patient, tumor and treatment 
characteristics, as well as maximum DAHANCA score for early and late 
dysphagia. The most frequent objective swallowing dysfunction was 
retention on MBS, occurring in 41 of the 65 patients (63%)[Table 1]. 
Penetration and aspiration was less common, 31% and 6%, 
respectively. The QoL data showed low degree of dysphagia with 
mean scores of 11-13, respectively. In general the different endpoints 
did not correlate well with each other indicating that they describe 
different aspects of swallowing morbidity. This difference was 
reflected in the correlations between swallowing endpoints and dose 
to the OAR. In general, complications observed on MBS and observer 
assessed late dysphagia correlated with the dose to superior and 
middle PCM (all p-values below 0.04), whereas quality of life 
endpoints correlated with dose-volume parameters in the larynx and 
supraglottic larynx (p values below 0.05).  
 
  
Conclusions: In this cohort of patients treated with IMRT, a high rate 
of retention was found on MBS whereas most other dysphagia-related 
endpoints occurred with a lower frequency. Significant relationships 
between dysphagia measures and dose-volume characteristics were 
found for specific OARs, especially the superior and middle PCM. 
Dysphagia is not sufficiently described using a single endpoint. 
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Purpose/Objective: To determine the impact of intensity-modulated 
radiotherapy (IMRT) in developing post-treatment hypothyroidism in 
nasopharyngeal carcinoma (NPC) patients, and to investigate the 
possible factors that could predict the onset of hypothyroidism. 
Materials and Methods: We retrospectively collected thyroid function 
of patient received radiotherapy for nasopharyngeal carcinoma at our 
hospital. Between January 2000 to December 2008, 191 patients were 
included into our study. There were 142 males and 49 females, with 
the median age of 48 years old. Table 1 summarized the 
characterisitcs of patients and treatment. Thyroid function was 
evaluated by measuring thyroid stimulating hormone (TSH) and serum 
free thyroxine(FT4). Elevated TSH level is documented as subclinical 
hypothyroidism and low level of FT4 is classified as clinical 
hypothyroidism. The risk factors analyzed in this study included age, 
gender, pathology, tumor and nodal extent, treatment modality, re-
irradiation, and chemotherapy. 
 
  
Results: With a median follow-up of 5.24 years (range, 0.18-12.2 
years), the incidence rates of clinical hypothyroidism in entire 
patients were 9.9%, 21.8 % and 43.3%, respectively in 3 years, 5 years, 
and 10 years follow up. In univariate analysis, subclinical 
hypothyroidism was more common in younger age (<30 years vs. 30 
years; P=0.022), advanced N stage (N3b vs. N0-3a; P=0.005), and IMRT 
group (IMRT vs. conventional radiotherapy; P<0.001). (Figure 1) While 
advanced T stage (T3-4 vs. T1-2; P<0.001), advanced N stage (N3b vs. 
N0-3a; P=0.045), and IMRT (IMRT vs. conventional radiotherapy; 
P<0.001) were significant factors that determine clinical 
hypothyroidism. IMRT group remained significant in developing both 
clinical (P<0.001) and subclinical (P<0.001) hypothyroidism in 
multivariate analysis while compared to traditional radiotherapy 
technique. The incidence rates of clinical hypothyroidism in IMRT 
group were 14.7 %, 42.3 % and 61.5 %, respectively in 3 years, 5 years, 
and 8 years follow up. 
 
  
Conclusions: More than half of NPC patients will experience clinical 
hypothyroidism after the treatment of IMRT. To avoid irreversibe 
damage, it is mandatory to set the proper dose constrain for thyroid 
organ in the future IMRT plan. 
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Purpose/Objective: Normal tissue biology may change during 
radiotherapy affecting function of organs at risk. The purpose of the 
study was to evaluate the changes of volume and proliferation level of 
